Approaches to Address Premature Death of Patients When Assessing Patterns of Use of Health Care Services after an Index Event

  • Montika Bush
  • , Ross J. Simpson
  • , Anna Kucharska-Newton
  • , Gang Fang
  • , Til Stürmer
  • , M. Alan Brookhart

Producción científica: Articlerevisión exhaustiva

3 Citas (Scopus)

Resumen

Background: Studies of the use of health care after the onset of disease are important for assessing quality of care, treatment disparities, and guideline compliance. Cohort definition and analysis method are important considerations for the generalizability and validity of study results. We compared different approaches for cohort definition (restriction by survival time vs. comorbidity score) and analysis method [Kaplan-Meier (KM) vs. competing risk] when assessing patterns of guideline adoption in elderly patients. Methods: Medicare beneficiaries aged 65-95 years old who had an acute myocardial infarction (AMI) in 2008 were eligible for this study. Beneficiaries with substantial frailty or an AMI in the prior year were excluded. We compared KM with competing risk estimates of guideline adoption during the first year post-AMI. Results: At 1-year post-AMI, 14.2% [95% confidence interval (CI), 14.0%-14.5%) of beneficiaries overall initiated cardiac rehabilitation when using competing risk analysis and 15.1% (95% CI, 14.8%-15.3%) from the KM analysis. Guideline medication adoption was estimated as 52.3% (95% CI, 52.0%-52.7%) and 53.4% (95% CI, 53.1%-53.8%) for competing risk and KM methods, respectively. Mortality was 17.0% (95%CI, 16.8%-17.3%) at 1 year post-AMI. The difference in cardiac rehabilitation initiation at 1-year post-AMI from the overall population was 0.1%, 1.7%, and 1.9% compared with 30-day survivor, 1-year survivor, and comorbidity-score restricted populations, respectively. Conclusions: In this study, the KM method consistently overestimated the competing risk method. Competing risk approaches avoid unrealistic mortality assumptions and lead to interpretations of estimates that are more meaningful.

Idioma originalEnglish
Páginas (desde-hasta)619-625
Número de páginas7
PublicaciónMedical Care
Volumen56
N.º7
DOI
EstadoPublished - 2018

Nota bibliográfica

Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.

Financiación

Supported by a National Service Research Award Pre-Doctoral/Post-Doctoral Traineeship from the Agency for Health Care Research and Quality sponsored by the Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Grant No. 5T32 S000032. T.S.: received investigator-initiated research funding and support as Principal Investigator (R01 AG023178; R01 AG056479) from the National In-stitute on Aging (NIA), and as Co-Investigator (R01 CA174453; R01 HL118255, R21-HD080214) from the National Institutes of Health (NIH). He also received salary support as Director of the Comparative Effectiveness Research (CER) Strategic Initiative, NC TraCS Institute, UNC Clinical and Translational Science Award (UL1TR001111), and as Director of the Center for Pharmacoepidemiology and research support from pharmaceutical companies (Amgen, AstraZeneca) to the Department of Epidemiology, University of North Carolina at Chapel Hill. He does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, BASF, AstraZeneca, Johnson & Johnson, and Novo Nordisk. The remaining authors declare no conflict of interest. Supported by a National Service Research Award Pre-Doctoral/Post-Doctoral Traineeship from the Agency for Health Care Research and Quality sponsored by the Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Grant No. 5T32 S000032. T.S.: received investigator-initiated research funding and support as Principal Investigator (R01 AG023178; R01 AG056479) from the National Institute on Aging (NIA), and as Co-Investigator (R01 CA174453; R01 HL118255, R21-HD080214) from the National Institutes of Health (NIH). He also received salary support as Director of the Comparative Effectiveness Research (CER) Strategic Initiative, NC TraCS Institute, UNC Clinical and Translational Science Award (UL1TR001111), and as Director of the Center for Pharmacoepidemiology and research support from pharmaceutical companies (Amgen, AstraZeneca) to the Department of Epidemiology, University of North Carolina at Chapel Hill. He does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, BASF, AstraZeneca, Johnson & Johnson, and Novo Nordisk. The remaining authors declare no conflict of interest.

FinanciadoresNúmero del financiador
Agency for Health Care Research and Quality
National In-stitute on Aging
National Park Service
National Institutes of Health (NIH)
National Institute on AgingR01 HL118255, R01 CA174453
National Institute on Aging
NIH National Institute of Child Health and Human Development National Center for Medical Rehabilitation ResearchR21HD080214
NIH National Institute of Child Health and Human Development National Center for Medical Rehabilitation Research
AstraZeneca
Johnson and Johnson Pharmaceutical Research and Development
Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill
University of North Carolina and North Carolina State UniversityUL1TR001111
University of North Carolina and North Carolina State University
BASF Corporation
University of North Carolina, Chapel HillR01 AG056479, R01 AG023178, 5T32 S000032
University of North Carolina, Chapel Hill
Novo Nordisk A/S

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Public Health, Environmental and Occupational Health

    Huella

    Profundice en los temas de investigación de 'Approaches to Address Premature Death of Patients When Assessing Patterns of Use of Health Care Services after an Index Event'. En conjunto forman una huella única.

    Citar esto